Answers are grounded in this paper and cite their sources.
Narrative review highlights challenges and potential of ctDNA in clinical settings for sarcoma subtypes.
Sarcomas represent a diverse group of mesenchymal tumors with high rates of recurrence after resection. While recent technical advances have enabled the detection of rare circulating tumor DNA (ctDNA) in other malignancies, the complexity and heterogeneity of sarcoma genomics have historically limited ctDNA in these cancers. This narrative review highlights the rapidly evolving evidence supporting potential clinical applications of ctDNA in common sarcoma subtypes including gastrointestinal stromal tumor, leiomyosarcoma, rhabdomyosarcoma, osteosarcoma, and Ewing sarcoma.
No takes yet. Share an insight, caveat, or question.
Goodsell et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: